Tamoxifen induces hypoxia in MCF-7 xenografts

Cancer Research

Volumn 57, Issue 22, 1997, Pages 5155-5161

  Evans, Sydney M ^a   Koch, Cameron J ^a   Laughlin, Kristine M ^a   Jenkins, W Timothy ^a   Van Winkle, Thomas ^a   Wilson, David F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITROIMIDAZOLE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; OXYGEN TENSION; PRIORITY JOURNAL; THROMBOGENICITY; TISSUE OXYGENATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL HYPOXIA; FEMALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OXYGEN; PARTIAL PRESSURE; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030724750     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fowble, B., Goodman, R. L., Glick, J. H., and Rosato, E. F. Locally advanced breast cancer. In: Mosby Year Book. St. Louis, MO: Mosby-Year Book Inc., 1991.
2. Fowble, B., Goodman, R. L., Glick, J. H., and Rosato, E. F. Local-regional recurrence following definitive treatment for operable breast cancer. In: Mosby Year Book. St. Louis, MO: Mosby-Year Book Inc., 1991.
3. Furman-Haran, E., Maretzek, A. F., Goldberg, I., Horowitz, A., and Degani, H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res., 54: 5511-5514, 1994.
4. Furman, E., Rushkin, E., Margalit, R., Bendel, P., and Degani, H. Tamoxifen-induced changes in MCF7 human breast cancer: in vivo and in vitro studies using nuclear magnetic resonance spectroscopy and imaging. J. Steroid Biochem. Mol. Biol., 43: 189-195, 1992.
5. Saphner, T., Tormey, D. C., and Gray, R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J. Clin. Oncol., 9: 286-294, 1991.
6. Anelli, T. F., Anelli, A., Tran, K. N., Lebwhol, D. E., and Borgen, P. I. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer (Phila.), 74: 74-77, 1994.
7. Moulder, J. E., and Rockwell, S. C. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys., 10: 695-712, 1984.
8. Woods, M. R., Lord, E. M., and Koch, C. J. Prediction of hypoxic radioresistance by monoclonal antibody reactive with 2-nitroimidazole adducts. Int. J. Radiat. Oncol. Biol. Phys., 34: 93-101, 1996.
9. 2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol., 26: 45-50, 1993.
10. Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., and Vaupel, P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res., 56: 4509-4515, 1996.
11. Nordsmark, M., Overgaard, M., and Overgaard, J. Pre-treatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol., 41: 31-39, 1996.
12. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher. R. L., and Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys., 38: 285-289, 1997.
13. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, L. J., Prosnitz, L. R., and Dewhirst, M. W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res., 56: 941-943, 1996.
14. Graeber, T. G., Osmanian, C., Jacks, T., Husman, T., Koch, C. E., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond.), 379: 88-91, 1996.
15. Reynolds, T. Y., Rockwell, S., and Glazer, P. M. Genetic instability induced by the tumor microenvironment. Cancer Res., 56: 5754-5757, 1996.
16. Stone, H. B., Brown, M. J., Phillips, T. L., and Sutherland, R. M. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Radiat. Res., 136: 422-434, 1993.
17. Olive, P., Banath, J., and Durand, R. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "Comet" assay. Radiat. Res., 122: 86-94, 1990.
18. Kennedy, A. S., Raleigh, J. A., Perez, G. M., Calkins, D. P., Thrall, D. E., Novotny, D. B., and Varia, M. A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys., 37: 897-905, 1997.
19. Koh, W. J., Rasey, J. S., Evans. M. L., Grierson, J. R., Lewellen, T. K., Graham, M. M., Krohn, K. A., and Griffin, T. W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys., 22: 199-212, 1991.
20. 123I]iodoazomycin arabinoside: preliminary report of a clinical study. Br. J. Cancer, 65: 90-95, 1992.
21. Lord, E. M., Harwell, L., and Koch, C. J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res., 53: 5271-5276, 1993.
22. Koch, C. J., Evans, S. M., and Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-l-y1)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies versus bound radioactivity. Br. J. Cancer, 72: 865-870, 1995.
23. Evans, S. M., Joiner, B. J., Jenkins, W, T., Laughlin, K. M., Lord, E. M., and Koch, C. J. Identification of hypoxia in cells and tissues of epigastric 9L rat tumours using EF5. Br. J. Cancer, 72: 875-882, 1995.
24. Evans, S. M., Jenkins, W. T., Joiner, B., Lord, E. M., and Koch, C. J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res., 56: 405-411, 1996.
25. Evans, S. M., Laughlin, K. M., Pugh, C. R., Sehgal, C. M., and Saunders, H. M. Use of power Doppler ultrasound-guided biopsies to location regions of tumor hypoxia. Br. J. Cancer, in press, 1997.
26. Wilson, D. F., and Cerniglia, G. J. Localization of tumors and evaluation of their state of oxygenation by phosphorescence imaging. Cancer Res., 52: 3988-3993, 1992.
27. Vinogradov, S. A., and Wilson, D. F. Metalotetrabenzopophyrins: new phosphorescent probes for oxygen measurements. J. Chem. Soc. Perkin. Trans. II: 103-111, 1995.
28. Lo, L-W., Koch, C. J., and Wilson, D. F. Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-caboxyphenyl) porphine: a phosphor with general application for measuring oxygen in biological systems. Anal. Biochem., 236: 153-160, 1996.
29. Cerniglia, G. J., Wilson, D. F., Pawlowski, M., Vinogradov, S., and Biaglow, J. E. Intravascular oxygen distribution in subcutaneous 9L tumors and radiation sensitivity. J. Appl. Phys., 82: 1939-1945, 1996.
30. Okunieff, P., Hockel, M., Dunphy, E. P., Schlenger, K., Knoop, C., and Vaupel, P. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. Int. J. Radiat. Biol. Oncol. Phys., 26: 631-636, 1993.
31. 2 tension measurements. Cancer Res., 51: 3316-3322, 1991.
32. Gottardis, M. M., Robinson, S. P., and Jordan, V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem., 20: 311-314, 1988.
33. Koch, C. J. A thin-film culturing technique allowing rapid gas-liquid equilibration (6 seconds) with no toxicity to mammalian cells. Radiat. Res., 97: 434-442, 1984.
34. Laughlin, K. M., Evans, S. M., Lord, E. M., and Koch, C. J. Biodistribution of EF5 [2-(2-nitro-1H-imidazol-l-y1)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in BALB/c mice bearing EMT6 tumors; implications for oxygen measurements in normal and tumor tissues. J. Pharmacol. Exp. Ther., 277; 1049-1057, 1996.
35. Evans, S. M., Jenkins, W. T., Shapiro, M., Laughlin, K., Chan, C., and Koch, C. J. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. Adv. Exp. Med. Biol., 411: 215-225, 1997.
36. Wouters, B. G., and Brown, J. M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiation therapy. Radiat. Res., 147: 541-550, 1997.
37. Pemberton, K. D., Melissari, E., and Kakkar, V. V. The influence of tamoxifen on the main natural anticoagulants and fibrinolysis. Blood Coagul. Fibrinolysis, 4: 935-942, 1993.
38. Willner, J., Kiricuta, I. C., and Kohbl, O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int. J. Radiat. Oncol. Biol. Phys., 37: 853-863, 1997.
39. Lee, J., Siemann, D. W., Koch, C. J., and Lord, E. M. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int. J. Cancer, 67: 372-378, 1996.
40. Montano, M. M., and Katzenellenbogen, B. S. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc. Natl. Acad. Sci. USA, 94: 2581-2586, 1997.
41. Gagliardi, A., and Collins, D. C. Inhibition of angiogenesis by antiestrogens. Cancer Res., 53: 533-535, 1993.
42. Gagliardi, A., Hennig, B., and Collins, D. C. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res., 16: 1101-1106, 1996.
43. Walenta, S., Salameh, A., Lyng, H., Evensen, J. F., Mitze, M., Rofstad, E. K., and Mueller-Kleiser, W. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am. J. Pathol., 150: 409-415, 1997.
44. Fisher, B. F., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., DeCillis, A., Hoehn, J. L., Lees, A. W., and Dimitrov, N. V. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst., 88: 1529-1542, 1996.
45. Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet, 339: 71-85, 1992.
46. Jordan, V. C., and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11: 578-610, 1990.
47. Gottardis, M. M., Jiang, S. Y., Jeng, M. H., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49: 4090-4093, 1989.
48. Borner, M. M., Bacchi, M., and Castiglione, M. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer. Eur. J. Cancer, 32A: 2173-2176, 1996.